Neoleukin Therapeutics Number Of Shares Shorted vs. Price To Book

NLTXDelisted Stock  USD 0.69  0.01  1.43%   
Based on Neoleukin Therapeutics' profitability indicators, Neoleukin Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Neoleukin Therapeutics' ability to earn profits and add value for shareholders.
For Neoleukin Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neoleukin Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neoleukin Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neoleukin Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neoleukin Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Please note, there is a significant difference between Neoleukin Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neoleukin Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neoleukin Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Neoleukin Therapeutics Price To Book vs. Number Of Shares Shorted Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Neoleukin Therapeutics's current stock value. Our valuation model uses many indicators to compare Neoleukin Therapeutics value to that of its competitors to determine the firm's financial worth.
Neoleukin Therapeutics is rated below average in number of shares shorted category among its peers. It is rated below average in price to book category among its peers . The ratio of Number Of Shares Shorted to Price To Book for Neoleukin Therapeutics is about  60,560 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neoleukin Therapeutics' earnings, one of the primary drivers of an investment's value.

Neoleukin Price To Book vs. Number Of Shares Shorted

Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Neoleukin Therapeutics

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
26.4 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Neoleukin Therapeutics

P/B

 = 

MV Per Share

BV Per Share

 = 
0.44 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Neoleukin Price To Book Comparison

Neoleukin Therapeutics is currently under evaluation in price to book category among its peers.

Neoleukin Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Neoleukin Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Neoleukin Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Neoleukin Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Neoleukin Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neoleukin Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.

Neoleukin Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Neoleukin Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neoleukin Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neoleukin Therapeutics' important profitability drivers and their relationship over time.

Use Neoleukin Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neoleukin Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neoleukin Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Neoleukin Therapeutics Pair Trading

Neoleukin Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Neoleukin Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neoleukin Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neoleukin Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neoleukin Therapeutics to buy it.
The correlation of Neoleukin Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neoleukin Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neoleukin Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neoleukin Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Neoleukin Therapeutics position

In addition to having Neoleukin Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Emerging Markets Funds Thematic Idea Now

Emerging Markets Funds
Emerging Markets Funds Theme
Fund or Etfs that invest in markets of developing countries. The Emerging Markets Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Consideration for investing in Neoleukin Stock

If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities